These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37316857)

  • 1. Exploring the depth and breadth of the genomics toolbox during the COVID-19 pandemic: insights from Aotearoa New Zealand.
    Bunce M; Geoghegan JL; Winter D; de Ligt J; Wiles S
    BMC Med; 2023 Jun; 21(1):213. PubMed ID: 37316857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic epidemiology of Delta SARS-CoV-2 during transition from elimination to suppression in Aotearoa New Zealand.
    Jelley L; Douglas J; Ren X; Winter D; McNeill A; Huang S; French N; Welch D; Hadfield J; de Ligt J; Geoghegan JL
    Nat Commun; 2022 Jul; 13(1):4035. PubMed ID: 35821124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 outbreaks in Aotearoa New Zealand: urgent action is required to address systematic causes and consequences of border failures.
    Kvalsvig A; Summers J; Gray L; Telfar-Barnard L; Baker MG
    N Z Med J; 2020 Dec; 133(1527):8-14. PubMed ID: 33332324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic surveillance during the first two years of the COVID-19 pandemic - country experience and lessons learned from Türkiye.
    Yalçın S; Coşgun Y; Dedeoğlu E; Kopp K; Bayrakdar F; Ünal G; Musul B; Sağtaş E; Korukluoğlu G; Raftery P; Kaygusuz S
    Front Public Health; 2024; 12():1332109. PubMed ID: 38855447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-Time Genomics for Tracking Severe Acute Respiratory Syndrome Coronavirus 2 Border Incursions after Virus Elimination, New Zealand.
    Douglas J; Geoghegan JL; Hadfield J; Bouckaert R; Storey M; Ren X; de Ligt J; French N; Welch D
    Emerg Infect Dis; 2021 Sep; 27(9):2361-2368. PubMed ID: 34424164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand.
    Geoghegan JL; Ren X; Storey M; Hadfield J; Jelley L; Jefferies S; Sherwood J; Paine S; Huang S; Douglas J; Mendes FK; Sporle A; Baker MG; Murdoch DR; French N; Simpson CR; Welch D; Drummond AJ; Holmes EC; Duchêne S; de Ligt J
    Nat Commun; 2020 Dec; 11(1):6351. PubMed ID: 33311501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 during Border Quarantine and Air Travel, New Zealand (Aotearoa).
    Eichler N; Thornley C; Swadi T; Devine T; McElnay C; Sherwood J; Brunton C; Williamson F; Freeman J; Berger S; Ren X; Storey M; de Ligt J; Geoghegan JL
    Emerg Infect Dis; 2021 May; 27(5):1274-1278. PubMed ID: 33734063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tracing the international arrivals of SARS-CoV-2 Omicron variants after Aotearoa New Zealand reopened its border.
    Douglas J; Winter D; McNeill A; Carr S; Bunce M; French N; Hadfield J; de Ligt J; Welch D; Geoghegan JL
    Nat Commun; 2022 Oct; 13(1):6484. PubMed ID: 36309507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the First SARS-CoV-2 Isolates from Aotearoa New Zealand as Part of a Rapid Response to the COVID-19 Pandemic.
    Harfoot R; Lawley B; Hernández LC; Kuang J; Grant J; Treece JM; LeQueux S; Day R; Jack S; Stanton JL; Bostina M; Ussher JE; Quiñones-Mateu ME
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic Surveillance for Monitoring Variants of Concern: SARS-CoV-2 Delta, Omicron, and Beyond.
    Guest PC
    Methods Mol Biol; 2022; 2511():407-413. PubMed ID: 35838978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The next phase in Aotearoa New Zealand's COVID-19 response: a tight suppression strategy may be the best option.
    Baker MG; Kvalsvig A; Crengle S; Harwood M; Tukuitonga C; Betty B; Bonning J; Wilson N
    N Z Med J; 2021 Nov; 134(1546):8-16. PubMed ID: 34855729
    [No Abstract]   [Full Text] [Related]  

  • 12. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
    Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C
    Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detecting the re-emergent COVID-19 pandemic after elimination: modelling study of combined primary care and hospital surveillance.
    Wilson N; Schwehm M; Verrall AJ; Parry M; Baker MG; Eichner M
    N Z Med J; 2020 Oct; 133(1524):28-39. PubMed ID: 33119568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of genomics in combating COVID-19 pandemic.
    Saravanan KA; Panigrahi M; Kumar H; Rajawat D; Nayak SS; Bhushan B; Dutt T
    Gene; 2022 May; 823():146387. PubMed ID: 35248659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-time estimation of the effective reproduction number of SARS-CoV-2 in Aotearoa New Zealand.
    Binny RN; Lustig A; Hendy SC; Maclaren OJ; Ridings KM; Vattiato G; Plank MJ
    PeerJ; 2022; 10():e14119. PubMed ID: 36275456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Negotiating Health Amidst COVID-19 Lockdown in Low-income Communities in Aotearoa New Zealand.
    Elers C; Jayan P; Elers P; Dutta MJ
    Health Commun; 2021 Jan; 36(1):109-115. PubMed ID: 33222539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continued mitigation needed to minimise the high health burden from COVID-19 in Aotearoa New Zealand.
    Baker MG; Kvalsvig A; Plank MJ; Geoghegan JL; Wall T; Tukuitonga C; Summers J; Bennett J; Kerr J; Turner N; Roberts S; Ward K; Betty B; Huang QS; French N; Wilson N
    N Z Med J; 2023 Oct; 136(1583):67-91. PubMed ID: 37797257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid Response to SARS-CoV-2 in Aotearoa New Zealand: Implementation of a Diagnostic Test and Characterization of the First COVID-19 Cases in the South Island.
    Lawley B; Grant J; Harfoot R; Treece JM; Day R; Hernández LC; Stanton JL; Ussher JE; Quiñones-Mateu ME
    Viruses; 2021 Nov; 13(11):. PubMed ID: 34835031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges of SARS-CoV-2 genomic surveillance in India during low positivity rate scenario.
    Tomar SS; Khairnar K
    Front Public Health; 2023; 11():1117602. PubMed ID: 37441634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early detection of SARS-CoV-2 variants through dynamic co-mutation network surveillance.
    Huang Q; Qiu H; Bible PW; Huang Y; Zheng F; Gu J; Sun J; Hao Y; Liu Y
    Front Public Health; 2023; 11():1015969. PubMed ID: 36755900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.